Register Login

EDESA BIOTECH, INC. (EDSA)

SymbolEDSA
NameEDESA BIOTECH, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address100 SPY COURT, MARKHAM, Ontario, L3R 5H6, Canada
Telephone+1 905 475-1234
Fax—
Email—
Websitehttps://www.edesabiotech.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001540159
Description

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The companys product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The companys EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

Additional info from NASDAQ:
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The companys product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The companys EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

2026-08-25 19:01

New Form SCHEDULE 13D/A - Edesa Biotech, Inc. <b>Filed:</b> 2026-08-25 <b>AccNo:</b> 0001171843-26-005738 <b>Size:</b> 18 KB

Read more
2026-08-25 17:39

New Form SCHEDULE 13D/A - Edesa Biotech, Inc. <b>Filed:</b> 2026-08-25 <b>AccNo:</b> 0000921895-26-002310 <b>Size:</b> 23 KB

Read more
2026-08-20 17:10

New Form 424B5 - Edesa Biotech, Inc. <b>Filed:</b> 2026-08-20 <b>AccNo:</b> 0001171843-26-005685 <b>Size:</b> 620 KB

Read more
2026-08-20 02:20

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

Read more
2026-08-19 20:01

Edesa Biotech Announces Proposed Public Offering

Read more
2026-08-19 17:06

New Form 424B5 - Edesa Biotech, Inc. <b>Filed:</b> 2026-08-19 <b>AccNo:</b> 0001171843-26-005653 <b>Size:</b> 626 KB

Read more
2026-08-13 20:15

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Read more
2026-07-02 21:05

Director Nijhawan Pardeep 🟢 acquired 3.4K shares of Edesa Biotech, Inc. (EDSA) Transaction Date: Jul 02, 2026 | Filing ID: 004451

Read more
2026-07-02 18:01

New Form S-3 - Edesa Biotech, Inc. <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0001171843-26-004449 <b>Size:</b> 409 KB

Read more
2026-06-26 18:05

New Form D - Edesa Biotech, Inc. <b>Filed:</b> 2026-06-26 <b>AccNo:</b> 0001493152-26-030335 <b>Size:</b> 11 KB

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06701656 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Beva… Phase2 Acute Respiratory Distress Syndrome (ARDS) Recruiting 2025-10-28 2028-09-01 ClinicalTrials.gov
NCT06701682 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilo… Phase2 Acute Respiratory Distress Syndrome (ARDS) Recruiting 2025-06-21 2028-09-01 ClinicalTrials.gov
NCT06703073 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) Phase2 Acute Respiratory Distress Syndrome (ARDS) Recruiting 2025-06-10 2028-09-01 ClinicalTrials.gov
NCT06701669 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Pari… Phase2 Acute Respiratory Distress Syndrome (ARDS) Recruiting 2025-06-10 2028-09-01 ClinicalTrials.gov
NCT04401475 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and… Phase2 COVID-19 Suspended 2020-11-25 2024-12-01 ClinicalTrials.gov
NCT03680131 Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatit… Phase2 Allergic Contact Dermatitis Completed 2019-10-15 2023-01-17 ClinicalTrials.gov
Total clinical trials: 6
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
SOC plus Placebo IV Other Phase PHASE2 COVID-19 SUSPENDED NCT04401475
SOC plus 15mg/kg EB05 IV Other Phase PHASE2 COVID-19 SUSPENDED NCT04401475
EB01 Cream 2.0% Other Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream 1.0% Other Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream 0.2% Other Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream Placebo Other Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort A: placebo DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
SOC plus Placebo IV OTHER Phase PHASE2 COVID-19 SUSPENDED NCT04401475
SOC plus 15mg/kg EB05 IV BIOLOGICAL Phase PHASE2 COVID-19 SUSPENDED NCT04401475
EB01 Cream 2.0% DRUG Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream 1.0% DRUG Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream 0.2% DRUG Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream Placebo DRUG Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
Total products: 96